Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA(R) (efavirenz) in HIV-1 Infected Pediatric Patients
Approval offers a once-daily option as part of a regimen for HIV-1 infected infants as young as three months and weighing at least 3.5 kg
Capsule sprinkle administration allows dosing in patients who cannot swallow capsules or tablets
PRINCETON, N...
Biopharmaceuticals, HIV/AIDS, FDA
Bristol-Myers Squibb, SUSTIVA, efavirenz
Biopharmaceuticals, HIV/AIDS, FDA
Bristol-Myers Squibb, SUSTIVA, efavirenz
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
SAN DIEGO, May 3, 2013 -- (Healthcare Sales & Marketing Network) -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chem...
Biopharmaceuticals
Ambrx, Bristol-Myers Squibb
Biopharmaceuticals
Ambrx, Bristol-Myers Squibb
SonaCare Medical to Launch FDA-Cleared Sonatherm(R) HIFU Surgical Ablation System at American Urology Association (AUA) Annual Meeting
Sonatherm is the Only Laparoscopic HIFU Device Cleared for Ablating Soft Tissue in the U.S.
CHARLOTTE, N.C., May 2, 2013 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, a leader in minimally invasive high intensity focused ultrasound (HI...
Devices, Oncology, Urology, Product Launch
SonaCare Medical, Sonatherm, HIFU, Surgical Ablation, prostate cancer
Devices, Oncology, Urology, Product Launch
SonaCare Medical, Sonatherm, HIFU, Surgical Ablation, prostate cancer
Millennium HealthCare Signs Distribution Agreement with Atossa Genetics
GARDEN CITY, N.Y., May 2, 2013 -- (Healthcare Sales & Marketing Network) -- Millennium HealthCare Inc. (OTC Pink: MHCC) today announced that its Medical Device subsidiary signed an agreement with Atossa Genetics Inc. (ATOS) for the distribution of Atossa'...
Devices, Diagnostics, Distribution
Millennium HealthCare, Atossa Genetics, ForeCYTE, Breast Health Test
Devices, Diagnostics, Distribution
Millennium HealthCare, Atossa Genetics, ForeCYTE, Breast Health Test
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Orthopedic Power Tools
CHARLOTTE, N.C.--(Healthcare Sales & Marketing Network)--The Premier healthcare alliance today announced new agreements for orthopedic power tools have been awarded to Brasseler USA of Savannah, Ga.; ConMed Linvatec of Largo, Fla.; and Stryker Sales Corpor...
Devices, Orthopaedic, Group Purchasing
Premier healthcare alliance, Brasseler, ConMed Linvatec, Stryker
Devices, Orthopaedic, Group Purchasing
Premier healthcare alliance, Brasseler, ConMed Linvatec, Stryker
Robotic Angioplasty Achieves 97.6 Percent Clinical Success Rate
Publication of PRECISE Trial Results in The Journal of American College of Cardiology builds on momentum of FDA clearance and commercialization of the CorPath® System
WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Corindus Vascular Robotics...
Devices, Interventional Cardiology
Corindus Vascular Robotics, CorPath, coronary angioplasty, robotic angioplasty
Devices, Interventional Cardiology
Corindus Vascular Robotics, CorPath, coronary angioplasty, robotic angioplasty
Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)
SOUTH SAN FRANCISCO, Calif., May 2, 2013 -- (Healthcare Sales & Marketing Network) -- Hyperion Therapeutics, Inc. (HPTX) today announced the exercise of its option to acquire BUPHENYL(R)(sodium phenylbutyrate) Tablets and Powder, an FDA approved therapy fo...
Biopharmaceuticals, Acquisitions
Hyperion Therapeutics, Valeant Pharmaceuticals, BUPHENYL, AMMONUL
Biopharmaceuticals, Acquisitions
Hyperion Therapeutics, Valeant Pharmaceuticals, BUPHENYL, AMMONUL
A.P. Pharma Appoints New Management Team
Barry D. Quart, Pharm.D. Appointed Chief Executive Officer
Robert Rosen Appointed President
Steve Davis Appointed Chief Operating Officer
REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--A.P. Pharma, Inc. (OTCBB:APPA.OB), a specialty ...
Biopharmaceuticals, Drug Delivery, Personnel
A.P. Pharma, Biochronomer, APF530
Biopharmaceuticals, Drug Delivery, Personnel
A.P. Pharma, Biochronomer, APF530
The Center for Wound Healing, Inc. Changes Name to RestorixHealth(R)
The Center for Wound Healing, Inc. has changed its name to RestorixHealth, giving further distinction to their expertise in developing and managing comprehensive wound care centers of excellence
Tarrytown, NY--(Healthcare Sales & Marketing Network)--The...
Devices, Wound Care
RestorixHealth, Center for Wound Healing, hyperbaric oxygen
Devices, Wound Care
RestorixHealth, Center for Wound Healing, hyperbaric oxygen
Wellsense Announces Research Presented at SAWC Demonstrates the M.A.P(TM) Helps Hospitals Achieve Their Goal of Zero Pressure Ulcers
New Research Presented at Symposium on Advanced Wound Care and Wound Healing Society Shows Improved Patient Outcomes and Significant Cost Savings
NASHVILLE, TN--(Healthcare Sales & Marketing Network) - Four studies presented at the Symposium on Advance...
Devices, Monitoring, Wound Care
Wellsense, Pressure Ulcer, bedside pressure mapping
Devices, Monitoring, Wound Care
Wellsense, Pressure Ulcer, bedside pressure mapping
Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President
NOVATO, Calif., May 1, 2013 -- (Healthcare Sales & Marketing Network) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced it has appointed Eric Yuen,...
Biopharmaceuticals, Personnel
Ultragenyx Pharmaceutical
Biopharmaceuticals, Personnel
Ultragenyx Pharmaceutical
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
PARSIPPANY, N.J., and MONTREAL, May 1, 2013 -- (Healthcare Sales & Marketing Network) -- Actavis, Inc. (ACT), and Valeant Pharmaceuticals International, Inc. (VRX) (VRX) today announced that Actavis Specialty Brands (the "Company") has acquired ...
Biopharmaceuticals, Acquisitions
Valeant Pharmaceuticals, Actavis, Metronidazole
Biopharmaceuticals, Acquisitions
Valeant Pharmaceuticals, Actavis, Metronidazole
William L. Ashton Joins Galena Biopharma's Board of Directors
LAKE OSWEGO, Ore., May 1, 2013 -- (Healthcare Sales & Marketing Network) -- Galena Biopharma (GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announ...
Biopharmaceuticals, Oncology, Personnel
Galena Biopharma
Biopharmaceuticals, Oncology, Personnel
Galena Biopharma
BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval
SAN ANTONIO, May 1, 2013 -- (Healthcare Sales & Marketing Network) -- BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, is among the first...
Devices, FDA
BiO2 Medical, Angel Catheter, Vena Cava Filter, Central Venous Catheter
Devices, FDA
BiO2 Medical, Angel Catheter, Vena Cava Filter, Central Venous Catheter
New Guidelines From American Association of Clinical Endocrinologists Recommend Medical Treatment of Obesity
First Guidelines to Incorporate Anti-Obesity Medications as Recommended Treatment for Cardiometabolic Diseases
MOUNTAIN VIEW, Calif., May 1, 2013 -- (Healthcare Sales & Marketing Network) -- A new comprehensive treatment algorithm for diabetes from the ...
Biopharmaceuticals, Endocrinology
VIVUS, Qsymia, obesity
Biopharmaceuticals, Endocrinology
VIVUS, Qsymia, obesity
Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors
Dynavax Meeting With FDA Scheduled First Half of June
BERKELEY, CA--(Healthcare Sales & Marketing Network) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company's board of directors has appointed Eddie Gray chief executive o...
Biopharmaceuticals, Personnel
Dynavax Technologies, HEPLISAV, hepatitis B vaccine
Biopharmaceuticals, Personnel
Dynavax Technologies, HEPLISAV, hepatitis B vaccine
Integra LifeSciences Introduces Hollywood(TM) VI Spinal Fusion System
Offers Surgeons a Variable Insertion Option and Multiple Implant Sizes
PLAINSBORO, N.J., April 30, 2013 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (IART) today announced the full market release of its Hollywoo...
Devices, Orthopaedic, Neurosurgery, Product Launch
Integra LifeSciences, Hollywood VI, interbody fusion
Devices, Orthopaedic, Neurosurgery, Product Launch
Integra LifeSciences, Hollywood VI, interbody fusion
NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
Product provides patients with benefits of home hemodialysis and greater treatment flexibility based on their clinical and lifestyle needs
LAWRENCE, Mass., April 30, 2013 -- (Healthcare Sales & Marketing Network) -- NxStage® Medical, Inc. (NXTM), a...
Devices, FDA
NxStage Medical, hemodialysis, home hemodialysis
Devices, FDA
NxStage Medical, hemodialysis, home hemodialysis
Kevin M. Smith Appointed to Zynex Board of Directors
LONE TREE, CO--(Healthcare Sales & Marketing Network) - Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the appointme...
Devices, Neurology, Personnel
Zynex, electrotherapy
Devices, Neurology, Personnel
Zynex, electrotherapy
St. Jude Medical Announces CE Mark and Launch of First Quadripolar CRT Pacemaker
Allure Quadra elevates the standard for Cardiac Resynchronization Therapy Pacemakers
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical device company, today announced CE Mark approval and European l...
Devices, Cardiology, Regulatory, Product Launch
St. Jude Medical, Allure Quadra, CRT-P, quadripolar, pacemaker
Devices, Cardiology, Regulatory, Product Launch
St. Jude Medical, Allure Quadra, CRT-P, quadripolar, pacemaker

